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The Association for Molecular Pathology’s Approach
to Supporting a Global Agenda to Embrace
Personalized Genomic MedicinePersonalized genomic medicine will play an important
role in future medical practice; today, however, it is still
surrounded by uncertainty. The call to action for a
national agenda for the future of Pathology in person-
alized medicine from the October 13–15 2010 meeting
at the Banbury Conference Center, proceedings of
which are being published this month in the American
Journal of Clinical Pathology,1 is a wake up call to pa-
thologists and laboratory medicine practitioners.
Whole genome analysis (WGA) testing, as well as vari-
ations such as whole exome and whole transcriptome
analysis, broaden the scope of questions that can be
asked in the clinical laboratory beyond traditional per-
sonalized medicine, enabling the adoption of person-
alized genomic medicine. Molecular pathologists and
diagnosticians should be—and indeed have been
since the dawn of molecular diagnostics three de-
cades ago—at the forefront of embracing new technol-
ogies and the analytical opportunities that result. We
have a responsibility to lead our colleagues in embrac-
ing this new era of genomic medicine or the discipline
of Pathology may be left behind.
Adoption of New Technologies
When a new technology with the potential to revolution-
ize medical practice is widely used in the research
setting, its translation into clinical care may engender
intense competition among specialties for ownership.
This issue is not new. Analogous to the recent Banbury
meeting, a group of approximately 50 pathologists
gathered in Bethesda, MD, in 1992. Their charge was
to discuss the future of Molecular Pathology (ie, the
application of novel molecular biology methods to the
practice of medicine). The Bethesda meeting led to
the establishment of the Association for Molecular Pa-
thology (AMP) in 1995, the development of Molecular
Genetic Pathology fellowship training programs ac-
credited by the Accreditation Council for Graduate
Medical Education, and the jointly administered spe-
cialty certification in Molecular Genetic Pathology bythe American Board of Pathology (ABP) and the Amer-
ican Board of Medical Genetics. In 1992, we faced
many of the same issues discussed at the Banbury
Conference Center in 2010: lack of expertise among
practicing pathologists and laboratory medicine prac-
titioners, an absence of quality standards for testing,
uncertainty of regulatory oversight for testing, non-ex-
istent billing codes, and incomplete knowledge about
many gene mutations identified by molecular tests.
The movement toward personalized genomic medi-
cine is real and inevitable. The model human genome
sequence was completed more than 10 years ago.
Extraordinary and nearly continuous improvements in
sequencing technologies are yielding faster and
cheaper sequence information. These developments
have brought us to the point where we are already
sequencing the genomes of individuals and finding
interesting and, at times, medically useful information.
As the $1000 genome becomes a reality in the next
two to five years, the number of individuals undergoing
WGA will rapidly increase. As practitioners dedicated
to laboratory and tissue-based diagnosis, pathologists
and other clinical laboratorians will be leaders in the
adoption of personalized genomic medicine. These
practitioners will play central roles in setting quality
standards for clinical WGA testing, performing clinical
WGA tests, interpreting test results, effectively report-
ing and communicating the clinical significance of re-
sults to treating health care providers and to patients,
and providing long-term specimen and/or data ar-
chiving. Moreover, pathologists and clinical laboratory
practitioners will be the drivers for incorporating trans-
lational genomic research findings into clinical prac-
tice, as we have done and continue to do for single
gene and disease-specific gene-panel testing in mo-
lecular pathology today.
The Banbury Conference Center Report
The specific proposed action list developed at the
2010 Banbury Conference Center articulates many of
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can move the practice of personalized genomic med-
icine into reality. Most pathologists and clinical labora-
tory practitioners need additional education in genom-
ics. Targeting current Pathology trainees is an obvious
and necessary approach; however, education is also
critical for other health care professionals to enable
them to interpret and understand the clinical signifi-
cance of WGA test results. Current multigene panels
will provide excellent initial experience in the applica-
tion of WGA technology as laboratories transition test-
ing to WGA platforms. Establishment of effective and
appropriate regulatory and reimbursement policies, in-
cluding quality standards and billing codes, will en-
courage movement of WGA from research to clinical
settings and will be essential for its widespread clinical
use. One of the most challenging projects outlined in
the Banbury Conference Center report1 is the develop-
ment of a clinical grade variant database. This effort
not only requires the cooperation and consensus of
many medical specialty groups, but it also demands
the creation of novel, clinically efficient interfaces to
aid pathologists and clinical laboratory practitioners in
the interpretation of WGA results as well as the capa-
bility for continual curation and updating of information
as our understanding of human genome variants
grows.
The Banbury Conference Center report1 drives home
the need for Pathology to embrace personalized
genomic medicine and outlines specific steps toward
achieving that goal. We would extend the term Pathol-
ogy to include not only ABP-certified pathologists but
also other specialists engaged in molecular diagnos-
tics (eg, from such diverse disciplines as genetics,
clinical chemistry/microbiology/immunology, and bioinfor-
matics, to name a few) to comprise the full breadth of
laboratorians and practitioners engaged in WGA test-
ing. It is also important to recognize that personalized
genomic medicine is an issue for the entire field of
medicine. The human genome carries information that
will impact every medical specialty. While Pathology
must embrace WGA testing and interpretation, every
medical specialty must understand the implications of
genomic variants for the care of their patients. The
education and training of today’s practicing physicians
includes little preparation on the human genome and
the clinical significance of genomic variation to health
and health care. The medical community now has the
task of integrating this new domain into medical prac-
tice, but Pathology cannot accomplish this alone. Part-
nerships across multiple specialties will be essential
for the care of individual patients because the results of
a single patient’s WGA will hold significance for multi-
ple medical disciplines. Paradoxically, Pathology and
Laboratory Medicine can only assume and maintain
leadership in personalized genomic medicine by part-
nering across the whole of medicine to reap the full
benefit of this promising future.Cautions for the Future
Although the eventual application of WGA for clinical
care is inevitable, the details and paths to their reso-
lution are unclear. As sequencing technology becomes
faster and less expensive and with higher density of
coverage of the genome, it is not clear whether storage
of sequence data for reinterpretation will be more
costly than repeating WGA, emphasizing the pivotal
role of bioinformatics in genomic medicine. Moreover,
with an estimated one quarter of human genes covered
by one or more patents, the impact of gene patents on
molecular pathology practice and the complexities of
related licensing and infringement issues are exponen-
tially amplified when patients’ entire genome sequences
are considered. For more information on this topic, see
AMP’s position statement on gene patents, available at
http://www.amp.org/publications_resources/position_
statements_letters/Gov/GenePatentPositionStatement_
Final_Nov2008.pdf. Failure to resolve the patentability
of human gene sequences and variant-phenotype as-
sociations in a medically responsible way risks the
imposition of an insurmountable barrier to the imple-
mentation of WGA.
Furthermore, the limited availability of genetic coun-
seling resources must be considered. An increased
number of variants will be identified, a significant pro-
portion of which are likely to be familial or private
variations of uncertain clinical significance. The inabil-
ity to ascertain and to provide meaningful cumulative
risk estimates for carrier or affected disease status
following WGA or whole exome analysis will pose par-
ticular problems. Therefore, in addition to clinically val-
idated standardized databases, interpretive algorithms
that consider variables such as age of disease onset,
penetrance, presence of pseudogenes, and likelihood
of phenocopies of the disease being evaluated must
be developed to facilitate accurate interpretation and
patient counseling.
Finally, in addition to physician and health care pro-
vider education, public education will be key to em-
powering broad interest and participation in personal-
ized genomic medicine by patients and their families.
Hand-in-hand with public education come the ethical
issues raised by the ability to sequence an individual’s
genome and potentially to predict medical risks as well
as other personal characteristics. These issues de-
serve, if not require, a public engagement process to
increase awareness and understanding as well as to facil-
itate recognition and design of public policies to pre-
vent unanticipated negative side effects. Attention to
these and other issues that will certainly arise as we
move forward will be essential to our success and the
realization of this bright future.
AMP Position
AMP stands alongside other organizations and stake-
holders in supporting an agenda to promote this new
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group of molecular diagnostics experts, we will spear-
head initiatives that ensure both a leading role for
Pathology and engagement of all health care provid-
ers. As evidence of this, AMP formed the Whole Ge-
nome Analysis Working Group in June 2010 to respond
to the health care and biomedical research communi-
ties and to provide education and practical guidelines
for the application of WGA to personalized genomic
medicine. AMP position statements on various topics
can be found at http://www.amp.org/publications_
resources/position_statements_letters/index.cfm. The ulti-
mate objectives of personalized genomic medicine are
better patient outcomes and healthier lives for every-with members from more than 30 countries, AMP
pledges to stress these goals and to continue to de-
velop and influence this exciting transition to person-
alized genomic medicine.
AMP Whole Genome Analysis Working Group
Reference
1. Tonellato PJ, Crawford JM, Boguski MS, Saffitz JE: A national agenda
for the future of pathology in personalized medicine: report of the
proceedings of a meeting at the Banbury Conference Center: genome-
era pathology, precision diagnostics and pre-emptive care: a stake-one. This is a global enterprise, and, as an organization holder summit. Am J Clin Pathol 2011, 135:668–672
Members of the Association for Molecular Pathology Whole Genome
Analysis Working Group: Jane Gibson (Chair) (University of Central Flor-
ida College of Medicine, Orlando FL), Nazneen Aziz (College of American
Pathologists, Northfield, IL), Pinar Bayrak-Toydemir (ARUP Laboratories,
Salt Lake City, UT), Philip Cotter* (ResearchDx, Irvine CA), Daniel H.
Farkas (Sequenom Center for Molecular Medicine, Grand Rapid, MI),
Andrea Ferreira-Gonzalez (Virginia Commonwealth University, Richmond,
VA), Manohar Furtado* (Life Technologies/Applied Biosystems, Foster
City, CA), Timothy C. Greiner (University of Nebraska Medical Center,
Omaha, NE), Tina Hambuch* (Illumina, Inc, San Diego, CA), Roger D.
Klein (Blood Center of Wisconsin, Milwaukee, WI), Debra G.B. Leonard
(Weill Cornell Medical College, New York, NY), Elaine Lyon* (ARUP Lab-
oratories), Karen P. Mann (Emory University, Atlanta, GA), Rong Mao
(ARUP Laboratories), Narasimhan Nagan* (Esoterix Genetic Laborato-
ries, LLC, successor to Genzyme Genetics,† Westborough, MA), Victoria
M. Pratt* (Quest Diagnostics, Nichols Institute, Manassas, VA), Iris Schri-
jver (Stanford University School of Medicine, Stanford, CA), Mark E. Sobel
(AMP Executive Officer, Bethesda, MD), Karl V. Voelkerding (University of
Utah and ARUP Laboratories, Salt Lake City, UT), Mary Steele Williams
(AMP Chief Operating Officer, Bethesda, MD).
*The following individuals disclosed relevant financial relationships:
P.C. is employed by and owns stock in Illumina, Inc.; M.F. is employed by
and owns stock in Life Technologies/Applied Biosystems; T.H. is em-
ployed by Illumina, Inc.; E.L. receives consulting fees from Novartis and
Canon; N.N. is employed by Esoterix Genetic Laboratories, LLC, succes-
sor to Genzyme Genetics†; V.P. is employed by and owns stock in Quest
Diagnostics.
†Genzyme Genetics is a trademark of Genzyme Corporation and used
by Esoterix Genetic Laboratories, LLC, a wholly-owned subsidiary of
LabCorp, under license. Esoterix Genetic Laboratories and LabCorp are
operated independently from Genzyme Corporation.
